Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 2.50 |
Expire Date | 2024-06-21 |
Day's Range | 0.0500 - 0.0700 |
Contract Range | N/A |
Volume | |
Open Interest | 742 |
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former Chairman of the Passage Bio Board of Directors and is open to students enrolled in life sciences
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-upCompleted dosing of Cohort 1 (n=5) in upliFT-D trial; on track to deliver 6-month safety and biomarker data from Cohort 1 in 2H 2024Plan to continue studying Dose 1 in Cohort 2 of upliFT-D trial; expect to initiate dosing by the end of 1H 2024, as plannedInitiated regulatory process with FDA